Tremfya (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years – Johnson & Johnson
Johnson & Johnson announced new data from the Tremfya (guselkumab) Phase III QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). Data from the… read more.




